SB revenue stream, if it is 100mln or +/- 15% is more or less certainty given how Japan and competition is performing..
this would give us comfortable 60% margin on products MC level..Gross margin..from product itself we can make over 40mln in Ebita per year...
another important factor of this revenue stream that it will fund other product developments..yes bring antimicrobial and Rececia ..
we can equally be positively surprised on another side when SP will hit 50..60c on FDA approval...still making it 800 MC company..with more to come...
what more to say here? Just wait 3 months
Price predictions, page-30
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |